573 related articles for article (PubMed ID: 32035041)
1. Updated assessment of risks and benefits of dolutegravir versus efavirenz in new antiretroviral treatment initiators in sub-Saharan Africa: modelling to inform treatment guidelines.
Phillips AN; Bansi-Matharu L; Venter F; Havlir D; Pozniak A; Kuritzkes DR; Wensing A; Lundgren JD; Pillay D; Mellors J; Cambiano V; Jahn A; Apollo T; Mugurungi O; Ripin D; Da Silva J; Raizes E; Ford N; Siberry GK; Gupta RK; Barnabas R; Revill P; Cohn J; Calmy A; Bertagnolio S
Lancet HIV; 2020 Mar; 7(3):e193-e200. PubMed ID: 32035041
[TBL] [Abstract][Full Text] [Related]
2. Risks and benefits of dolutegravir-based antiretroviral drug regimens in sub-Saharan Africa: a modelling study.
Phillips AN; Venter F; Havlir D; Pozniak A; Kuritzkes D; Wensing A; Lundgren JD; De Luca A; Pillay D; Mellors J; Cambiano V; Bansi-Matharu L; Nakagawa F; Kalua T; Jahn A; Apollo T; Mugurungi O; Clayden P; Gupta RK; Barnabas R; Revill P; Cohn J; Bertagnolio S; Calmy A
Lancet HIV; 2019 Feb; 6(2):e116-e127. PubMed ID: 30503325
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of public-health policy options in the presence of pretreatment NNRTI drug resistance in sub-Saharan Africa: a modelling study.
Phillips AN; Cambiano V; Nakagawa F; Revill P; Jordan MR; Hallett TB; Doherty M; De Luca A; Lundgren JD; Mhangara M; Apollo T; Mellors J; Nichols B; Parikh U; Pillay D; Rinke de Wit T; Sigaloff K; Havlir D; Kuritzkes DR; Pozniak A; van de Vijver D; Vitoria M; Wainberg MA; Raizes E; Bertagnolio S;
Lancet HIV; 2018 Mar; 5(3):e146-e154. PubMed ID: 29174084
[TBL] [Abstract][Full Text] [Related]
4. Risks and Benefits of Dolutegravir- and Efavirenz-Based Strategies for South African Women With HIV of Child-Bearing Potential: A Modeling Study.
Dugdale CM; Ciaranello AL; Bekker LG; Stern ME; Myer L; Wood R; Sax PE; Abrams EJ; Freedberg KA; Walensky RP
Ann Intern Med; 2019 May; 170(9):614-625. PubMed ID: 30934067
[TBL] [Abstract][Full Text] [Related]
5. The potential role of long-acting injectable cabotegravir-rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis.
Phillips AN; Bansi-Matharu L; Cambiano V; Ehrenkranz P; Serenata C; Venter F; Pett S; Flexner C; Jahn A; Revill P; Garnett GP
Lancet Glob Health; 2021 May; 9(5):e620-e627. PubMed ID: 33770513
[TBL] [Abstract][Full Text] [Related]
6. Dolutegravir versus efavirenz in women starting HIV therapy in late pregnancy (DolPHIN-2): an open-label, randomised controlled trial.
Kintu K; Malaba TR; Nakibuka J; Papamichael C; Colbers A; Byrne K; Seden K; Hodel EM; Chen T; Twimukye A; Byamugisha J; Reynolds H; Watson V; Burger D; Wang D; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
Lancet HIV; 2020 May; 7(5):e332-e339. PubMed ID: 32386721
[TBL] [Abstract][Full Text] [Related]
7. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.
Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Gaolethe T; Petlo C; Lockman S; Holmes LB; Makhema J; Shapiro RL
Lancet Glob Health; 2018 Jul; 6(7):e804-e810. PubMed ID: 29880310
[TBL] [Abstract][Full Text] [Related]
8. 72 weeks post-partum follow-up of dolutegravir versus efavirenz initiated in late pregnancy (DolPHIN-2): an open-label, randomised controlled study.
Malaba TR; Nakatudde I; Kintu K; Colbers A; Chen T; Reynolds H; Read L; Read J; Stemmet LA; Mrubata M; Byrne K; Seden K; Twimukye A; Theunissen H; Hodel EM; Chiong J; Hu NC; Burger D; Wang D; Byamugisha J; Alhassan Y; Bokako S; Waitt C; Taegtmeyer M; Orrell C; Lamorde M; Myer L; Khoo S;
Lancet HIV; 2022 Aug; 9(8):e534-e543. PubMed ID: 35905752
[TBL] [Abstract][Full Text] [Related]
9. Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa.
Marseille E; Kahn JG; Mmiro F; Guay L; Musoke P; Fowler MG; Jackson JB
Lancet; 1999 Sep; 354(9181):803-9. PubMed ID: 10485721
[TBL] [Abstract][Full Text] [Related]
10. Real-world use and outcomes of dolutegravir-containing antiretroviral therapy in HIV and tuberculosis co-infection: a site survey and cohort study in sub-Saharan Africa.
Romo ML; Brazier E; Mahambou-Nsondé D; De Waal R; Sekaggya-Wiltshire C; Chimbetete C; Muyindike WR; Murenzi G; Kunzekwenyika C; Tiendrebeogo T; Muhairwe JA; Lelo P; Dzudie A; Twizere C; Rafael I; Ezechi OC; Diero L; Yotebieng M; Fenner L; Wools-Kaloustian KK; Shah NS; Nash D;
J Int AIDS Soc; 2022 Jul; 25(7):e25961. PubMed ID: 35848120
[TBL] [Abstract][Full Text] [Related]
11. HIV-1 integrase resistance associated mutations and the use of dolutegravir in Sub-Saharan Africa: a systematic review and meta-analysis protocol.
Semengue ENJ; Santoro MM; Ndze VN; Dambaya B; Takou D; Teto G; Nka AD; Fabeni L; Wiyeh A; Ceccherini-Silberstein F; Colizzi V; Perno CF; Fokam J
Syst Rev; 2020 Apr; 9(1):93. PubMed ID: 32334643
[TBL] [Abstract][Full Text] [Related]
12. Brief Report: Weight Gain Following ART Initiation in ART-Naïve People Living With HIV in the Current Treatment Era.
Ruderman SA; Crane HM; Nance RM; Whitney BM; Harding BN; Mayer KH; Moore RD; Eron JJ; Geng E; Mathews WC; Rodriguez B; Willig AL; Burkholder GA; Lindström S; Wood BR; Collier AC; Vannappagari V; Henegar C; Van Wyk J; Curtis L; Saag MS; Kitahata MM; Delaney JAC
J Acquir Immune Defic Syndr; 2021 Mar; 86(3):339-343. PubMed ID: 33148997
[TBL] [Abstract][Full Text] [Related]
13. A randomized comparison of health-related quality of life outcomes of dolutegravir versus efavirenz-based antiretroviral treatment initiated in the third trimester of pregnancy.
Ochanda PN; Lamorde M; Kintu K; Wang D; Chen T; Malaba T; Myer L; Waitt C; Reynolds H; Khoo S
AIDS Res Ther; 2022 Jun; 19(1):24. PubMed ID: 35672853
[TBL] [Abstract][Full Text] [Related]
14. Predicted effects of the introduction of long-acting injectable cabotegravir pre-exposure prophylaxis in sub-Saharan Africa: a modelling study.
Smith J; Bansi-Matharu L; Cambiano V; Dimitrov D; Bershteyn A; van de Vijver D; Kripke K; Revill P; Boily MC; Meyer-Rath G; Taramusi I; Lundgren JD; van Oosterhout JJ; Kuritzkes D; Schaefer R; Siedner MJ; Schapiro J; Delany-Moretlwe S; Landovitz RJ; Flexner C; Jordan M; Venter F; Radebe M; Ripin D; Jenkins S; Resar D; Amole C; Shahmanesh M; Gupta RK; Raizes E; Johnson C; Inzaule S; Shafer R; Warren M; Stansfield S; Paredes R; Phillips AN;
Lancet HIV; 2023 Apr; 10(4):e254-e265. PubMed ID: 36642087
[TBL] [Abstract][Full Text] [Related]
15. Safety and pharmacokinetics of dolutegravir in pregnant mothers with HIV infection and their neonates: A randomised trial (DolPHIN-1 study).
Waitt C; Orrell C; Walimbwa S; Singh Y; Kintu K; Simmons B; Kaboggoza J; Sihlangu M; Coombs JA; Malaba T; Byamugisha J; Amara A; Gini J; Else L; Heiburg C; Hodel EM; Reynolds H; Mehta U; Byakika-Kibwika P; Hill A; Myer L; Lamorde M; Khoo S
PLoS Med; 2019 Sep; 16(9):e1002895. PubMed ID: 31539371
[TBL] [Abstract][Full Text] [Related]
16. Raltegravir versus efavirenz in antiretroviral-naive pregnant women living with HIV (NICHD P1081): an open-label, randomised, controlled, phase 4 trial.
João EC; Morrison RL; Shapiro DE; Chakhtoura N; Gouvèa MIS; de Lourdes B Teixeira M; Fuller TL; Mmbaga BT; Ngocho JS; Njau BN; Violari A; Mathiba R; Essack Z; Pilotto JHS; Moreira LF; Rolon MJ; Cahn P; Prommas S; Cressey TR; Chokephaibulkit K; Werarak P; Laimon L; Hennessy R; Frenkel LM; Anthony P; Best BM; Siberry GK; Mirochnick M
Lancet HIV; 2020 May; 7(5):e322-e331. PubMed ID: 32386720
[TBL] [Abstract][Full Text] [Related]
17. Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon.
Calmy A; Tovar Sanchez T; Kouanfack C; Mpoudi-Etame M; Leroy S; Perrineau S; Lantche Wandji M; Tetsa Tata D; Omgba Bassega P; Abong Bwenda T; Varloteaux M; Tongo M; Mpoudi-Ngolé E; Montoyo A; Mercier N; LeMoing V; Peeters M; Reynes J; Delaporte E;
Lancet HIV; 2020 Oct; 7(10):e677-e687. PubMed ID: 33010241
[TBL] [Abstract][Full Text] [Related]
18. Viral load non-suppression status among women exposed to Dolutegravir-based versus Efavirenz-based regimens in Ethiopia: A before-and-after study.
Facha W; Tadesse T; Wolka E; Astatkie A
PLoS One; 2024; 19(6):e0305331. PubMed ID: 38857273
[TBL] [Abstract][Full Text] [Related]
19. Cost-Utility Analysis of a Dolutegravir-Based Versus Low-Dose Efavirenz-Based Regimen for the Initial Treatment of HIV-Infected Patients in Cameroon (NAMSAL ANRS 12313 Trial).
Bousmah MA; Nishimwe ML; Tovar-Sanchez T; Lantche Wandji M; Mpoudi-Etame M; Maradan G; Omgba Bassega P; Varloteaux M; Montoyo A; Kouanfack C; Delaporte E; Boyer S;
Pharmacoeconomics; 2021 Mar; 39(3):331-343. PubMed ID: 33355914
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
